II. Electronic Access

In order to receive these guidance documents via your fax machine, call the CDRH FOD system at 800–899–0381 or 301–827–0111 from a touch-tone telephone. Press 1 to enter the system and enter the document number listed above followed by the pound sign (#). Follow the remaining voice prompts to complete your request.

Persons interested in obtaining a copy of these guidance documents may do so by using the Internet. CDRH maintains an entry on the Internet for easy access to information including text, graphics, and files that may be downloaded to a personal computer with access to the Internet. Updated on a regular basis, the CDRH home page includes these guidance documents, device safety alerts, **Federal Register** reprints, information on premarket submissions (including lists of approved applications and manufacturers' addresses), small manufacturers' assistance, information on video conferencing and electronic submissions, mammography matters, and other device-oriented information. The CDRH home page may be accessed at http://www.fda.gov/cdrh. These guidance documents are also available at http://www.fda.gov/cdrh/ODE.

III. Comments

Interested persons may submit to the Dockets Management Branch (address above) written comments regarding these guidance documents by July 18, 2000. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number for each guidance document as listed in the table in the **SUPPLEMENTARY INFORMATION** section of this document. If you wish to comment on more than one guidance document, please submit your comments separately for each guidance document. The guidance documents and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: April 3, 2000.

Linda S. Kahan,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 00–9710 Filed 4–18–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Industry Grassroots Meeting: Report on Partnership Activities

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA), Office of Regulatory Affairs, San Francisco District Office is announcing the following meeting entitled ''Industry Grassroots Meeting: Report on Partnership Activities.'' The purpose of the meeting is to report the Partnership Among Industry and Regulators (PAIR) Committee activities and to solicit input from participants for future activities and projects for the PAIR Committee. The PAIR Committee was formed as a result of an action item coming out of a similar grassroots meeting held at the Oakland Federal Bldg. in January of 1997.

Date and Time: The meeting will be held on May 10, 2000, from 8 a.m. to 5 p.m.

Location: The meeting will be held at the Oakland Federal Bldg., North Tower, 3d Floor Auditorium, 1301 Clay St., Oakland, CA 94612.

Contact: Jake Pearson, San Francisco District Office (HFR–PA 160), 510–337–6877, FAX 510–337–6701, e-mail jpearson@ora.fda.gov, or Kathryn D. Macropol (HFR–PA 140), 510–337–6867, e-mail kmacropo@ora.fda.gov, Food and Drug Administration, 1431 Harbor Bay Pkwy., Alameda, CA 94502. Information is also available at the PAIR website at http://www.pair-ca.org.

Registration: There is no charge to attend the meeting; however, registration is required. The meeting is open to all interested in management and regulatory affairs activities of industries regulated by FDA. While attendance would most benefit those industries located in Northern California, all interested groups are encouraged to attend. You may register via the Internet at http://www.pair-ca.org and by completing the online registration form. Alternatively, you can register by sending your name, title, firm name, address, telephone, fax number, and e-mail address (if available) to the contacts listed above. Please include any topics of interest you would like to have included in the program.

If you need special accommodations due to a disability, please notify Jake Pearson at least 7 days in advance.

Dated: April 12, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 00–9712 Filed 4–18–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99D–4201]

Guidance for Industry: Dioxin in Anti-caking Agents Used in Animal Feed and Feed Ingredients; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a revised guidance for industry (#98) entitled ''Dioxin in Anti-caking Agents Used in Animal Feed and Feed Ingredients.'' The guidance is intended to notify members of the feed industry of recent findings regarding the presence of dioxins congeners that may be present in anti-caking agents in animal feeds and to offer general advice regarding monitoring of these products. This guidance has been revised in response to comments.

DATES: Submit written comments at any time.

ADDRESSES: Submit written comments on this guidance document to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Copies of the guidance document entitled ''Dioxin in Anti-caking Agents Used in Animal Feed and Feed Ingredients'' may be obtained on the Internet from the CVM home page at http://www.fda.gov/cvm/fda/TOCs/guideline.html. Persons without Internet access may submit written requests for single copies of the guidance to the Communications Staff (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests.

FOR FURTHER INFORMATION CONTACT:

For general questions regarding the guidance document: Judy A. Gushee, Center for Veterinary Medicine (HFV–230), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0150, e-mail: jgushee@cvm.fda.gov.

For scientific questions regarding the guidance document: Randall A.